Analysts Offer Predictions for AngioDynamics FY2028 Earnings

Key Points

• Zacks Research predicts AngioDynamics will report an EPS of ($0.04) for FY2028, an improvement from the consensus estimate of ($0.37) for the current fiscal year.
• Several brokerages have issued positive ratings for AngioDynamics, with Lake Street Capital setting a target price of $24.00 and Canaccord Genuity raising their target to $17.00.
• AngioDynamics reported a quarterly revenue increase of 13.0% year-over-year, with actual earnings of ($0.03) per share, outperforming analysts' expectations.

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Investment analysts at Zacks Research issued their FY2028 earnings estimates for shares of AngioDynamics in a research report issued to clients and investors on Tuesday, August 5th. Zacks Research analyst R. Department expects that the medical instruments supplier will post earnings of ($0.04) per share for the year. The consensus estimate for AngioDynamics' current full-year earnings is ($0.37) per share.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.09. The business had revenue of $80.16 million during the quarter, compared to analysts' expectations of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The company's revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.06) EPS.

ANGO has been the topic of a number of other research reports. HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of AngioDynamics in a report on Wednesday, July 16th. Canaccord Genuity Group lifted their price target on AngioDynamics from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Wednesday, July 16th. Finally, Lake Street Capital initiated coverage on AngioDynamics in a report on Wednesday, July 16th. They issued a "buy" rating and a $24.00 price target for the company.

AngioDynamics Price Performance

Shares of ANGO traded down $0.02 during mid-day trading on Wednesday, reaching $8.51. 719,168 shares of the company's stock were exchanged, compared to its average volume of 809,494. The business's fifty day simple moving average is $9.64 and its 200-day simple moving average is $9.79. The stock has a market capitalization of $345.76 million, a PE ratio of -10.25 and a beta of 0.67. AngioDynamics has a 52-week low of $5.83 and a 52-week high of $13.50.

Institutional Trading of AngioDynamics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC purchased a new position in shares of AngioDynamics in the 2nd quarter worth $139,000. Bastion Asset Management Inc. grew its stake in AngioDynamics by 46.5% during the second quarter. Bastion Asset Management Inc. now owns 959,043 shares of the medical instruments supplier's stock worth $9,810,000 after buying an additional 304,217 shares during the period. Pier Capital LLC raised its stake in shares of AngioDynamics by 40.5% in the 2nd quarter. Pier Capital LLC now owns 694,235 shares of the medical instruments supplier's stock valued at $6,887,000 after acquiring an additional 200,244 shares during the period. Y Intercept Hong Kong Ltd lifted its holdings in shares of AngioDynamics by 890.3% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 224,514 shares of the medical instruments supplier's stock valued at $2,227,000 after acquiring an additional 201,843 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its position in AngioDynamics by 13.5% during the 2nd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,747 shares of the medical instruments supplier's stock worth $166,000 after purchasing an additional 1,989 shares during the period. Hedge funds and other institutional investors own 89.43% of the company's stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.